AL
NBIX icon

Airain Ltd’s Neurocrine Biosciences NBIX Stock Holding History

Airain Ltd’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,341
Closed -$967K – 985
2017
Q1 		$967K Buy
+22,341
New +$957K 0.05% 350
2016
Q1 		– Sell
-11,740
Closed -$664K – 977
2015
Q4 		$664K Buy
+11,740
New +$597K 0.05% 395
2015
Q3 		– Sell
-61,692
Closed -$2.95M – 993
2015
Q2 		$2.95M Buy
+61,692
New +$2.62M 0.17% 161

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Airain Ltd's NBIX Position: Q2 2017 in Review

Airain Ltd sold out of Neurocrine Biosciences (NBIX) in Q2 2017, closing a stake of 22,341 shares — an estimated $967K sold.

Airain Ltd first reported a position in NBIX in Q2 2015 and held it in 3 quarters. The position peaked at $2.95M in Q2 2015. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

  • Airain Ltd reported no remaining Neurocrine Biosciences position as of Q2 2017 after selling out during the quarter.
  • Airain Ltd sold 22,341 Neurocrine Biosciences shares in Q2 2017, an estimated $967K.
  • Airain Ltd first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 3 quarters.
  • Airain Ltd's Neurocrine Biosciences position peaked at $2.95M in Q2 2015.
  • 221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.